Johnson & Johnson Launches India’s First Pulsed Field Ablation System for Atrial Fibrillation Treatment

 Johnson & Johnson: In a major medical milestone for cardiovascular care, Johnson & Johnson has announced the regulatory approval of the VARIPULSE™ Platform in India. This marks the introduction of the country’s first Pulsed Field Ablation (PFA) technology, an advanced innovation already utilized in more than 80,000 catheter ablation procedures globally to treat atrial fibrillation (AFib).

AFib is a progressive condition characterized by an irregular and often rapid heartbeat caused by uncoordinated electrical signals in the atria. If left untreated, it significantly spikes the risks of stroke, heart failure, and overall mortality.

The Growing AFib Burden in India:
Atrial Fibrillation affects approximately 50 million people worldwide. In India, the prevalence is estimated to impact between 0.1% and 1.6% of the population, translating to roughly 5 million people currently living with the condition.

The disease presents unique challenges within the Indian demographic:

Earlier Onset: Indian patients typically develop AFib nearly a decade earlier than Western populations, at an average age of 55.

Delayed Detection: Underlying AFib is detected at the time of an acute stroke in 20% to 45% of cases.

Severe Consequences: Early intervention is critical to reducing stroke risks, a pressing concern given that India accounted for 773,000 stroke deaths in 2021 alone (10% of the global total).

How the Integrated VARIPULSE™ Platform Works:
Catheter ablation is a minimally invasive technique that restores normal heart rhythm by treating areas responsible for faulty electrical signaling. Traditional methods rely on thermal energy, but PFA uses short, high-voltage electrical pulses to create microscopic pores in cardiac cell membranes, leading to targeted cell death without damaging surrounding tissues.

The VARIPULSE™ Platform stands out as the first PFA technology fully integrated with the CARTO™ 3 electroanatomical mapping system. This 3D mapping technology provides electrophysiologists with real-time visualization. This unified workflow drives:

• Enhanced efficiency and reproducibility.
• Procedural accuracy and precise targeting.
• Patient-centric therapy with minimal to no fluoroscopy (X-ray) exposure.
• Compatibility with both deep and conscious sedation.

“Bringing an integrated platform like VARIPULSE™ to India will enable physicians to deliver more precise and efficient care for AFib patients,” stated Randeep Sharma, General Manager, India, Electrophysiology, MedTech, Johnson & Johnson.

Strong Real-World Clinical Evidence:
The regulatory approval is backed by robust data from major international clinical registries highlighting the platform’s safety and efficacy:

VARIPURE (Europe): The largest prospective real-world dataset for the platform in Europe reported an 84.2% freedom from documented atrial arrhythmia recurrence at 12 months. It demonstrated a strong safety profile with a low 0.8% primary adverse event (PAE) rate and zero reported strokes or coronary spasms.

Real AF (US & Canada): This prospective, multicenter registry revealed a 0.6% primary adverse event rate with zero PFA-related complications, alongside an impressive 86.5% same-day discharge rate.

Dr. Dhanunjaya Lakkireddy, Executive Medical Director and Professor of Medicine at the Kansas City Heart Rhythm Institute, noted that PFA is a rapidly emerging technology that can revolutionize arrhythmia care in India. He emphasized that integrating PFA with 3D mapping empowers specialists with superior therapeutic tools to drastically improve patient quality of life.